Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
<p><strong>Introduction: </strong>Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m<sup>2</sup> administered on days 1,4,8 and 11 of a 21 day cyc...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2012-01-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/article/view/10316 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p><strong>Introduction: </strong>Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m<sup>2</sup> administered on days 1,4,8 and 11 of a 21 day cycle), with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM).</p><p><strong>Methods: </strong>We treated a MM patient with<strong> </strong>Cystic Fibrosis with Bortezomib alone to avoid the use of corticosteroid and consequently the risk of lung infection reactivations, first of all due to the patient <em>Pseudomonas aeruginosa</em> colonization. Bortezomib was administrated at 1.3 mg/m<sup>2</sup> on days 1,4,8 and 11 with a 10 day rest period and four 21-day cycles were administered. We evaluate the treatment response and toxicity.</p><p><strong>Results: </strong>After four cycles of therapy the patient achieved a<strong> </strong>very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects.</p><p><strong>Conclusions:</strong> Bortezomib can be successfully utilized for the management of this difficult disease situation</p> |
|---|---|
| ISSN: | 2035-3006 |